Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18891499 | SYSTEMS AND METHODS FOR METABOLIC OUTCOME PREDICTIONS | September 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18407393 | SYSTEMS AND METHODS FOR MACHINE LEARNING-BASED PREDICTIVE MATCHING | January 2024 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18472036 | INTEGRATED DIAGNOSTIC TEST REQUISITION AND CLINICAL DECISION SUPPORT | September 2023 | December 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18207299 | METHOD FOR DIAGNOSIS AND DOCUMENTATION OF HEALTHCARE INFORMATION | June 2023 | April 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18178513 | Methods and systems for connecting subjects to healthcare providers | March 2023 | March 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18063834 | SYSTEMS AND METHODS FOR MEDICAL INFORMATION DATA WAREHOUSE MANAGEMENT | December 2022 | September 2024 | Allow | 22 | 0 | 0 | Yes | No |
| 18077918 | PERSONAL AND REUSABLE INFECTION STATUS PASSPORT DEVICE THAT IS CONFIGURED TO TEST FOR COVID-19 AND INFECTIOUS DISEASE | December 2022 | March 2025 | Allow | 28 | 4 | 0 | No | No |
| 18073064 | AN APPARATUS FOR ENHANCING LONGEVITY AND METHOD FOR ITS USE | December 2022 | August 2024 | Abandon | 20 | 5 | 0 | Yes | No |
| 17917056 | PARENT-AND-CHILD HEALTH STUDY ASSISTANCE SYSTEM, PARENT-AND-CHILD HEALTH STUDY ASSISTANCE APPARATUS, AND DATA PROCESSING METHOD | October 2022 | March 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17812728 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING PROGRAM | July 2022 | March 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17532227 | Systems and Methods for Identifying Content Based on User Interactions | November 2021 | April 2025 | Abandon | 40 | 4 | 0 | Yes | No |
| 17511721 | METHOD FOR GENERATING A DIAGNOSIS MODEL USING BIOMARKER GROUP-RELATED VALUE INFORMATION, AND METHOD AND DEVICE FOR DIAGNOSING MULTI-CANCER USING THE SAME | October 2021 | November 2024 | Abandon | 37 | 5 | 0 | Yes | No |
| 17405750 | SYSTEMS FOR MONITORING ROOMS IN A MEDICAL FACILITY | August 2021 | June 2025 | Abandon | 46 | 3 | 0 | Yes | No |
| 17309975 | SYSTEMS AND METHODS FOR USING DEEP LEARNING TO GENERATE ACUITY SCORES FOR CRITICALLY ILL OR INJURED PATIENTS | July 2021 | March 2025 | Allow | 44 | 8 | 0 | Yes | No |
| 17101867 | MEDICATION MANAGEMENT DEVICE, MEDICATION MANAGEMENT METHOD, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM STORING MEDICATION MANAGEMENT PROGRAM | November 2020 | November 2024 | Abandon | 48 | 3 | 0 | Yes | No |
| 17024557 | INFUSION SYSTEMS AND METHODS FOR PATIENT PREDICTIONS USING ASSOCIATION MINING | September 2020 | April 2025 | Abandon | 55 | 6 | 0 | Yes | No |
| 17009094 | METHODS AND SYSTEMS FOR SECURE DATA ANALYSIS AND MACHINE LEARNING | September 2020 | June 2025 | Allow | 57 | 5 | 0 | Yes | No |
| 16900812 | MACHINE LEARNING TECHNIQUES FOR UPDATING MEDICAL DECISIONS BASED ON EVENT DATA FROM FIELD DEVICES | June 2020 | November 2024 | Abandon | 54 | 5 | 0 | No | No |
| 16893139 | SYSTEM FACILITATING HEALTHCARE SERVICES AND A METHOD THEREOF | June 2020 | March 2025 | Abandon | 57 | 4 | 0 | No | No |
| 16881317 | SYSTEMS AND METHODS FOR PATIENT-TRIAL MATCHING | May 2020 | September 2024 | Allow | 52 | 4 | 0 | Yes | No |
| 16864887 | ELDERLY MORTALITY AFTER TRAUMA PREDICTION SYSTEM WITH MULTI-STAGE MODELLING AND REPORTING | May 2020 | January 2025 | Abandon | 57 | 4 | 0 | No | No |
| 16693540 | PRECISION COHORT ANALYTICS FOR PUBLIC HEALTH MANAGEMENT | November 2019 | May 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16531291 | GENERATING HIGH CONFIDENCE REFILLS FOR UNIFIED WORKFORCE MANAGEMENT | August 2019 | March 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16377011 | Patient Care System | April 2019 | December 2024 | Abandon | 60 | 7 | 0 | No | No |
| 16332953 | A SYSTEM AND METHOD FOR USE IN ASSISTING A USER TO FOCUS ON PERFORMING A PERSONAL CARE ACTIVITY | March 2019 | June 2024 | Allow | 60 | 6 | 0 | Yes | No |
| 16155758 | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE | October 2018 | December 2024 | Abandon | 60 | 7 | 0 | Yes | No |
| 15423533 | SYSTEMS, DEVICES, AND METHODS FOR PROVIDING INTERACTIVE PHARMACY SERVICES | February 2017 | February 2025 | Abandon | 60 | 7 | 0 | Yes | Yes |
| 14730144 | COMPUTATIONAL MEDICAL TREATMENT PLAN METHOD AND SYSTEM WITH MASS MEDICAL ANALYSIS | June 2015 | December 2021 | Abandon | 60 | 7 | 0 | Yes | Yes |
| 14657790 | MEDICAL DEVICE WITH NATURAL LANGUAGE PROCESSOR | March 2015 | September 2024 | Allow | 60 | 12 | 1 | Yes | No |
| 14604425 | SYSTEMS AND METHODS FOR FACILITATING PHYSIOLOGICAL DATA COLLECTION PRIOR TO APPOINTMENT | January 2015 | January 2020 | Allow | 60 | 3 | 0 | No | No |
| 14556326 | MANAGING COMPANIONSHIP DATA | December 2014 | January 2019 | Allow | 49 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSELEY, GREGORY D.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOSELEY, GREGORY D works in Art Unit 3681 and has examined 29 patent applications in our dataset. With an allowance rate of 34.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.
Examiner MOSELEY, GREGORY D's allowance rate of 34.5% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOSELEY, GREGORY D receive 4.38 office actions before reaching final disposition. This places the examiner in the 100% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MOSELEY, GREGORY D is 52 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +22.1% benefit to allowance rate for applications examined by MOSELEY, GREGORY D. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 8.3% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 1% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 18% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 1% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 36% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 36% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.